New cancer vaccine could save’millions of lives,’ according to researchers.


New cancer vaccine could save’millions of lives,’ according to researchers.

Researchers working on a vaccine to prevent cancer from spreading inside the body have made a breakthrough, which the team hopes will save “millions of lives.”

According to Cancer Research UK, there are over 166,000 cancer deaths in the UK each year, or more than 450 every day. In Britain, overall cancer death rates have reduced by 17% since the early 1970s, yet far too many people are still dying from the disease. Following the remarkable work of scientists and drugmakers to develop many vaccines against COVID-19 in a matter of months, experts predict a breakthrough in the fightback will be made shortly.

In a study led by scientists at Weill Cornell Medicine at NewYork-Presbyterian University Hospital, a new technique for creating cancer vaccines has showed promise.

The preclinical findings, according to the scientists, could lead to vaccines that cause the immune system to target malignancies early in their development, stopping the disease from spreading.

Although the concept of generating a cancer vaccine is not new, this strategy focuses on determining whether or not it is possible to prevent cancer rather than treat it.

“There have been many trials that have sought to employ cancer vaccines as a therapeutic, not as a prevention, but those have largely been unsuccessful,” said Dr. Steven Lipkin, vice chair for research in the Weill Department of Medicine.

This is because tumors might evolve techniques to elude the patient’s natural immune response once they have developed in the human body.

“However, we’ve known for many years that when malignancies initially begin, when they’re at the level of a single cancer cell that has just converted or a few cancer cells, that’s when they’re most vulnerable,” Dr. Lipkin continued.

Researchers focused on Lynch syndrome, the most frequent genetic propensity to gastrointestinal cancer, to start building a potential cancer vaccine.

Lynch syndrome mutations can produce human DNA abnormalities, and improper repair of these flaws during normal cell division predisposes them to cancer.

The changes also allow cancer cells to create altered proteins known as neoantigens, which the immune system may recognize and attack.

The researchers used a mouse model of Lynch syndrome to identify the most prevalent neoantigens found in the tumors of the mice.

“We then employed computational approaches to.” Brinkwire Summary News, continued Dr. Lipkin.


Comments are closed.